IMATINIB ALKALOID-INT 400 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

imatinib alkaloid-int 400 mg

synthon hispania s.l. - spania - imatinibum - compr. film. - 400mg - alte antineoplazice inhibitori de protein-kinaza

IMATINIB AUROBINDO 100 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

imatinib aurobindo 100 mg

polisano pharmaceuticals s.a. - romania - imatinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza

IMATINIB AUROBINDO 400 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

imatinib aurobindo 400 mg

polisano pharmaceuticals s.a. - romania - imatinibum - compr. film. - 400mg - alte antineoplazice inhibitori de protein-kinaza

IMATINIB GRINDEKS 100 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

imatinib grindeks 100 mg

as grindeks - letonia - imatinibum - caps. - 100mg - inhibitori de protein-kinaza

Vanflyta Uniunea Europeană - română - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leucemie mieloidă - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.